Pulmonary Fibrosis

Latest News

Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com
Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

February 13th 2025

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.

IPF Top 5 of 2024 | Image Credit: Venngage
Top 5 Most-Read IPF Content of 2024

December 23rd 2024

Man yawning at work | Image Credit: LIGHTFIELD STUDIOS - stock.adobe.com
Patients With ILD Face Higher Burden of Fatigue, Excessive Daytime Sleepiness

December 13th 2024

Highlights from ERS Congress 2024
ICYMI: Highlights From ERS Congress 2024

December 6th 2024

Year in Review: Idiopathic Pulmonary Fibrosis
Year in Review: Idiopathic Pulmonary Fibrosis

December 4th 2024

Breaking Ground in IPF Care: 2024 Year-in-Review

Discover the latest advancements in idiopathic pulmonary fibrosis (IPF) care. Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.

Discover the latest advancements in idiopathic pulmonary fibrosis (IPF) care. Our 2024 Year-in-Review: Idiopathic Pulmonary Fibrosis highlights breakthroughs, clinical trial insights, and emerging therapies shaping the future of IPF management.

More News

Stethoscope on stack of books | Image credit: ronstik – stock.adobe.com
July 10th 2024

Pulmonary Fibrosis, Macrophage Research Jumped Since 2020

Hayden E. Klein
The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.
IPF | Image credit: Sviatlana – stock.adobe.com
July 3rd 2024

Study Identifies P2RX7 as Key Player in IPF Pathogenesis, Therapy

Hayden E. Klein
Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).
Person taking pills | Image credit: fizkes – stock.adobe.com
June 28th 2024

Many Patients With IPF Continue on Antifibrotics for 3 Years

Hayden E. Klein
However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.
Clinical research graphic shaped like lightbulb | image credit: ArtemisDiana – stock.adobe.com
June 25th 2024

Report Highlights Advancements in 2024 Idiopathic Pulmonary Fibrosis Pipeline

Hayden E. Klein
More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.
Woman running hand through hair | Image credit: Alessandro Grandini – stock.adobe.com
June 12th 2024

Hair Metabolome May Help Diagnose Pulmonary Fibrosis

Hayden E. Klein
The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.
Image of lungs and a doctor with a vial labelled COVID-19 | Image credit: Image credit: Mongkolchon - stock.adobe.com
June 11th 2024

IPF and COPD Associated With Poor COVID-19 Outcomes

Kevin Kunzmann
Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.
Lungs
August 6th 2020

Patients With IPF Are at Increased Risk for Multiple Cancers

Skylar Jeremias
Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.
Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF
July 25th 2020

Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF

Jaime Rosenberg
In the last 3 months of life, health care costs were significantly lower for patients receiving multidisciplinary collaborative care than for patients receiving specialized care or nonspecialized care. The differences in costs were primarily driven by differences in hospitalizations and emergency department visits.
Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis
June 5th 2020

Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis

Rachel Lutz
The study sought to determine whether patient-reported outcomes are linked with death beyond clinical risk factors in patients with idiopathic pulmonary fibrosis (IPF).
Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds
January 25th 2020

Nintedanib Exhibits Superior Cost-effectiveness to Pirfenidone for Treatment of IPF, Study Finds

Alison Rodriguez
Researchers compared the cost-effectiveness of ninetedanib to pirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF) and found nintedanib to be more cost-saving than pirfenidone, according to study findings.
Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis
January 17th 2020

Emerging Therapeutic Innovations for Treatment of Idiopathic Pulmonary Fibrosis

Matthew Gavidia
Researchers highlight new therapeutic attempts and potential future approaches to treating idiopathic pulmonary fibrosis, a chronic, fibrosing idiopathic interstitial lung disease.
Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF
May 18th 2019

Concurrent Decline in FVC, Walking Test More Likely Associated With Disease Progression in IPF

Samantha DiGrande
In a study to be presented at the American Thoracic Society (ATS) Annual Meeting, held in Dallas, Texas on May 17-22, 2019, researchers investigated visit-to-visit variability in the forced vital capacity (FVC) of patients with idiopathic pulmonary fibrosis (IPF).
Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF
May 10th 2019

Real-World Study Finds High Adherence, Persistence With Pirfenidone Treatment in IPF

Samantha DiGrande
During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet) in the treatment of idiopathic pulmonary fibrosis (IPF) in a real-world setting.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo